NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Cardiff Oncology, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCRDF
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CRDF COVERAGE

What’s moving Cardiff Oncology, Inc. now

Current reporting with the operating signal separated from the noise.

01
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most

Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most

Investors are testing whether Cardiff Oncology, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CRDF filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

SEC feed temporarily unavailable

No verified filing is shown until the official endpoint responds.

EARNINGS / QUARTERLY TRACKER

Cardiff Oncology, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.